Work Here?
Overview
Ampersand Biomedicines develops modular therapeutics designed to act only in specific target tissues to improve efficacy and safety in disease treatment. Its products pair a localizing element that directs therapy to diseased tissues with an actuator that restores healthy biology, enabling precision medicine that reduces on-target, off-tissue toxicity. The company earns revenue through partnerships, licensing agreements, and potential direct sales of its therapeutics, working with pharmaceutical companies and healthcare providers. A key differentiator is its programmable, tissue-focused approach that combines disease-specific targeting with controllable therapeutic action, aiming to minimize side effects. The company’s goal is to advance its modular, tissue-localized platform and expand its therapeutic offerings through partnerships and funding, such as the $50 million investment from Flagship Pioneering.
About Ampersand
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$115M
Headquarters
Boston, Massachusetts
Founded
2020
Simplify's Take
What believers are saying
- Secured $65M Series B from Flagship Pioneering and Eli Lilly in November 2024.
- Partnered with Pfizer on obesity programs using AND Platform in November 2024.
- Acquired AbCheck on January 3, 2024, accelerating antibody discovery capabilities.
What critics are saying
- Pfizer terminates obesity collaboration after Lilly's retatrutide Phase 3 data in 2025.
- AbCheck integration fails from Affimed IP disputes, delaying programs 18 months.
- Generate Biomedicines' GD-1 enters clinic first, capturing 40% IO partnerships by Q4 2025.
What makes Ampersand unique
- AND Platform creates modular AND-Body therapeutics localized to diseased tissues only.
- Address Map computationally identifies precise tissue targets avoiding off-tissue toxicity.
- Combines localizer for anchoring and actuator for disease-specific biology restoration.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$115M
Above
Industry Average
Funded Over
2 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -4%Ampersand Biomedicines secured $65 million in Series B funding to advance its drug delivery technology, Address, Navigate, and Design (AND), which targets disease-specific tissues to minimize side effects. The funding, led by Flagship Pioneering and new investor Eli Lilly, will support preclinical research in immuno-oncology and immuno-inflammation. Ampersand also has collaborations with Pioneering Medicines and Pfizer focused on obesity.
$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company Two lead programs in...
Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets. Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target. Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company
Akagera National Park in Rwanda has acquired two electric motorcycles from the company Ampersand to use for wildlife tracking and park operations.
Ampersand Biomedicines has announced the acquisition of antibody discovery technology company AbCheck, previously a wholly-owned subsidiary of Affimed.
There are no jobs for Ampersand right now.
Find jobs on Simplify and start your career today
About Ampersand
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$115M
Headquarters
Boston, Massachusetts
Founded
2020
There are no jobs for Ampersand right now.
Find jobs on Simplify and start your career today